Calcium-activated potassium channel family in coronary artery bypass grafts

Wen-Tao Sun1, Hai-Tao Hou1, Huan-Xin Chen1

  • 1Center for Basic Medical Research & Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Insights

Calcium-activated potassium (KCa) channels are key in blood vessel dilation. This study found differences in KCa subtype distribution between internal thoracic artery and saphenous vein grafts, highlighting BKCa

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Vascular Biology

Background:

  • Coronary artery bypass graft (CABG) surgery relies on graft patency, influenced by vasodilatation.
  • Calcium-activated potassium (KCa) channels regulate vascular tone, but their role in different graft types is not fully understood.
  • Internal thoracic artery (ITA) and saphenous vein (SV) are common CABG conduits with distinct properties.

Purpose of the Study:

  • To investigate the expression, distribution, and functional contribution of KCa channel subtypes (BKCa, IKCa, SKCa) in ITA and SV.
  • To elucidate the role of these KCa channels in endothelium-smooth muscle interactions governing graft vasodilatation.
  • To understand how KCa channel characteristics impact the postoperative performance of CABG grafts.

Main Methods:

  • Real-time polymerase chain reaction and Western blot for KCa channel mRNA and protein.
  • Immunohistochemistry to determine the tissue distribution of KCa channel subtypes.
  • Wire myography to assess KCa subtype-mediated vasorelaxation.

Main Results:

  • All KCa channel subtypes (BKCa, IKCa, SKCa) are expressed in both ITA and SV endothelium and smooth muscle.
  • ITA shows greater smooth muscle abundance of BKCa and greater endothelial abundance of SKCa, unlike the even distribution in SV.
  • BKCa significantly contributes to ITA vasodilatation, with a limited role in SV.

Conclusions:

  • KCa channels are abundant in both ITA and SV, with distinct subtype distributions in vascular layers.
  • The significant role of BKCa in ITA vasodilatation suggests its therapeutic potential for preventing ITA spasm post-CABG.
  • Understanding these KCa channel differences can inform strategies to improve graft function and patient outcomes.
Abstract

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.4K
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
5.5K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
10.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.6K